시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 칼시토닌 유전자 관련 펩타이드(CGRP) 억제제 시장 보고서(2025년)
Calcitonin Gene-Related Peptide (CGRP) Inhibitors Global Market Report 2025
상품코드 : 1760496
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,217,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 8,987,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,756,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

칼시토닌 유전자 관련 펩타이드(CGRP) 억제제 시장 규모는 향후 몇 년 동안 빠르게 성장할 것으로 예상되며, 2029년까지 10.2%의 CAGR로 46억 8,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안 성장의 원동력은 편두통의 유병률 증가, 편두통 예방 치료의 보급, 환자 인식 증가, 의료 지출 증가입니다. 예측 기간 동안 예상되는 주요 동향으로는 약물 제제 기술의 발전, 디지털 헬스 툴의 통합, 정밀 의료의 발전, 바이오시밀러의 기술 개선 등이 있습니다.

편두통 발생 건수의 증가는 향후 몇 년 동안 칼시토닌 유전자 관련 펩타이드(CGRP) 억제제 시장의 성장에 크게 기여할 것으로 예상됩니다. 편두통은 맥박이 뛰는 듯한 통증을 특징으로 하는 심각한 두통의 일종으로, 보통 머리의 한쪽을 침범하며, 메스꺼움, 구토, 빛과 소리에 대한 과민반응을 동반하는 경우가 많습니다. 편두통의 증가는 스트레스 수준의 증가가 주요 원인으로 꼽히고 있습니다. 지속적인 스트레스는 편두통을 유발하는 특정 신경 경로를 활성화하기 때문에 CGRP 억제제는 급성 및 장기 치료 전략에 적합한 표적화된 예방적 치료 접근법을 제공함으로써 편두통 관리에 중요한 역할을 하고 있습니다. 이들 약물은 CGRP 수용체를 효과적으로 차단하여 편두통 발작의 빈도와 강도를 감소시켜 삶의 질을 개선하고 일상 생활 수행 능력을 향상시킵니다. 예를 들어, 2023년 1월 미국 국립의학도서관(National Library of Medicine)은 편두통이 전 세계 인구의 14-15%에 영향을 미치며, 전 세계 질병 부담의 4.9%를 차지한다고 보고했습니다. 따라서 편두통의 발생률 증가는 CGRP 억제제 시장의 수요를 증가시키고 있습니다.

CGRP 수용체 길항제는 CGRP 수용체의 활성을 억제하여 편두통의 통증을 예방하는 약물의 일종으로, CGRP 수용체 길항제는 편두통의 통증을 예방하기 위해 CGRP 수용체의 활성을 억제하는 약물의 일종입니다. 예를 들어, 2023년 4월 미국 생명공학 기업 AbbVie Inc.는 미국 식품의약국(FDA)으로부터 성인 만성 편두통 예방 치료제로 QULIPTA(Atogepant)를 승인받았습니다. 큐리프타는 경구용 CGRP 수용체 길항제로, 편두통 발병에 관여하는 CGRP 경로를 차단하여 편두통 발생을 억제하는 약물입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

ksm
영문 목차

영문목차

Calcitonin gene-related peptide (CGRP) inhibitors are a category of drugs that block the function of the CGRP pathway, which plays a role in transmitting pain and widening blood vessels in the brain. These inhibitors help to decrease both the frequency and intensity of migraines and are used as a treatment for patients suffering from chronic or episodic migraines.

The primary types of CGRP inhibitors include monoclonal antibodies, small molecules, and peptides. Monoclonal antibodies are lab-engineered molecules designed to bind specifically to a single target, such as a protein or receptor in the body. Their mechanisms of action involve anti-CGRP ligand therapies and CGRP receptor antagonists. Administration methods vary and include oral, nasal, and intravenous routes. Treatment options are categorized into preventive and acute therapies for migraines. End users of these treatments include hospitals, specialty clinics, mail-order pharmacies, and retail pharmacies.

The calcitonin gene-related peptide (CGRP) inhibitors market research report is one of a series of new reports from The Business Research Company that provides calcitonin gene-related peptide (CGRP) inhibitors market statistics, including calcitonin gene-related peptide (CGRP) inhibitors industry global market size, regional shares, competitors with a calcitonin gene-related peptide (CGRP) inhibitors market share, detailed calcitonin gene-related peptide (CGRP) inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the calcitonin gene-related peptide (CGRP) inhibitors industry. This calcitonin gene-related peptide (CGRP) inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The calcitonin gene-related peptide (CGRP) inhibitors market size has grown rapidly in recent years. It will grow from $2.87 billion in 2024 to $3.17 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth during the historic period can be attributed to rising investments in research and development, an increase in the approval of new drugs, growing demand for non-opioid pain relievers, and a stronger emphasis on personalized medicine.

The calcitonin gene-related peptide (CGRP) inhibitors market size is expected to see rapid growth in the next few years. It will grow to $4.68 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. Growth during the forecast period can be driven by the increasing prevalence of migraines, greater adoption of preventive migraine treatments, rising patient awareness, and higher healthcare expenditures. Key trends expected in the forecast period include advancements in drug formulation technologies, integration of digital health tools, progress in precision medicine, and technological improvements in biosimilars.

The rising occurrence of migraine is anticipated to contribute significantly to the growth of the calcitonin gene-related peptide (CGRP) inhibitors market in the coming years. Migraine is a severe type of headache characterized by pulsating pain, typically affecting one side of the head, and often accompanied by symptoms such as nausea, vomiting, and heightened sensitivity to light and sound. The increasing migraine cases are largely attributed to elevated stress levels, as ongoing stress activates certain neural pathways that can trigger migraine episodes. CGRP inhibitors play a key role in migraine management by providing a targeted and preventative treatment approach that fits both acute and long-term care strategies. These medications reduce the frequency and intensity of migraine attacks by effectively blocking CGRP receptors, leading to improved quality of life and enhanced daily performance. For example, in January 2023, the National Library of Medicine, a U.S.-based health information agency, reported that migraines affect between 14% and 15% of the global population and account for 4.9% of the global disease burden. Hence, the growing incidence of migraine is boosting demand in the CGRP inhibitors market.

Leading companies in the CGRP inhibitors space are investing in innovative therapies and seeking regulatory approvals for advanced treatment options, such as CGRP receptor antagonists, to enhance migraine relief, broaden clinical use, and provide user-friendly delivery methods like oral or intranasal formulations. A CGRP receptor antagonist is a type of medication that prevents migraine pain by inhibiting CGRP receptor activity. For instance, in April 2023, AbbVie Inc., a biotech firm based in the U.S., obtained approval from the U.S. Food and Drug Administration (FDA) for QULIPTA (atogepant) for the preventive treatment of chronic migraine in adults. QULIPTA is an oral CGRP receptor antagonist that works by blocking CGRP pathways involved in migraine pathogenesis, thereby reducing the occurrence of migraine episodes.

In October 2022, Pfizer Inc., a U.S.-based pharmaceutical company, acquired Biohaven Pharmaceutical Holding Company Ltd. for roughly $11.6 billion. This acquisition was aimed at expanding Pfizer's portfolio of migraine therapies and supporting long-term market growth by integrating Biohaven's innovative CGRP-targeted treatments with Pfizer's extensive global infrastructure. Biohaven Pharmaceutical Holding Company Ltd. is a U.S.-based biopharmaceutical firm known for its work in developing CGRP inhibitors for migraine management.

Major players in the calcitonin gene-related peptide (cgrp) inhibitors market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Kissei Pharmaceutical Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., Shin Nippon Biomedical Laboratories Ltd., Sosei Group Corporation, Nuvie Bio Inc., Vaxxinity Inc., Acherx LLC, AfaSci Inc.

North America was the largest region in the calcitonin gene-related peptide (CGRP) inhibitors market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in calcitonin gene-related peptide (CGRP) inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the calcitonin gene-related peptide (CGRP) inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The calcitonin gene-related peptide (CGRP) inhibitors market consists of sales of aimovig, emgality, ubrogepant, rimegepant, atogepant, and ajovy. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Calcitonin Gene-Related Peptide (CGRP) Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on calcitonin gene-related peptide (cgrp) inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for calcitonin gene-related peptide (cgrp) inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The calcitonin gene-related peptide (cgrp) inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Characteristics

3. Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Trends And Strategies

4. Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Growth Analysis And Strategic Analysis Framework

6. Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Segmentation

7. Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Regional And Country Analysis

8. Asia-Pacific Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

9. China Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

10. India Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

11. Japan Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

12. Australia Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

13. Indonesia Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

14. South Korea Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

15. Western Europe Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

16. UK Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

17. Germany Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

18. France Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

19. Italy Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

20. Spain Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

21. Eastern Europe Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

22. Russia Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

23. North America Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

24. USA Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

25. Canada Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

26. South America Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

27. Brazil Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

28. Middle East Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

29. Africa Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

30. Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Competitive Landscape And Company Profiles

31. Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Other Major And Innovative Companies

32. Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

34. Recent Developments In The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

35. Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기